OCGN Ocugen Inc

Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results

Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results

MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced that it will host a conference call to provide a business update and discuss its first quarter 2022 financial results at 8:30 a.m. ET on Friday, May 6, 2022.

Ocugen will issue a pre-market earnings announcement on the same day. Investors are invited to participate on the call using the following details:

  • Dial-In Number: (844) 873-7330 (toll free) or (602) 563-8473 (Int’l)
  • Conference ID: 6995784
  • Webcast: Available in and archived for approximately 45 days following the call

About Ocugen, Inc.

Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at and follow us on and .

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Ocugen Contact:

Ken Inchausti

Head, Investor Relations & Communications

Please submit investor-related inquiries to:



EN
02/05/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocugen Inc

 PRESS RELEASE

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025...

Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET Enrollment for the OCU400 Phase 3 liMeliGhT clinical trial—the first and largest gene therapy registrational trial for broad retinitis pigmentosa patients—was completed. Topline Phase 3 data expected in the first quarter 2027, advancing OCU400 towards potential approval in 2027.OCU410ST Phase 2/3 pivotal confirmatory trial nearing enrollment completion. Interim data expected in the third quarter 2026, followed by topline Phase 2/3 data in the second qu...

 PRESS RELEASE

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a...

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline Phase 3 data expected in 1Q 2027, advancing OCU400 towards potential approval in 2027 as a treatment option for early- to late-stage RPPositive long-term, 3-year Phase 1/2 durable, safety and tolerability data for OCU400 demonstrates sustained clinically mea...

 PRESS RELEASE

Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M...

Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results MALVERN, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company’s fourth quarter and full year 2025 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 4, 2026. Ocugen will issue a pre-market earnin...

 PRESS RELEASE

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Chief Financial Officer (CFO). “Mrs. Johnson-Greene’s diverse background across a variety of strategic roles at organizations representing many facets of the industry make her well-suited to serve as Ocugen’s CFO,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “We look forw...

 PRESS RELEASE

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registere...

Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock MALVERN, Pa., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced underwritten registered direct offering of 15,000,000 shares of its common stock at an offering price of $1.50 per share of common stock for net proceeds of $20.85 million, after deducting commissions and other estimated offering expenses payable by Ocugen. The financing was led by...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch